End-stage hip disease
Conditions
Interventions
Ropivacaine group:100mg(10ml) of ropivacaine was diluted with normal saline to 50ml and injected into multiple points with a thin needle around the hip joint
Bupivacaine liposome group:Bupivacaine liposome 266mg (20ml) was diluted with normal saline to 50ml, and multi-point injection was made with a fine needle around the hip joint
Sponsors
The Second Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients diagnosed with hip arthritis or necrosis of the femoral head undergoing elective unilateral total hip replacement for the first time, >=18 years of age, ASA grade I-III
Exclusion criteria
Exclusion criteria: 1. Total hip replacement surgery due to trauma, hip dysplasia, tumor or ankylosing spondylitis; 2. History of previous hip surgery of the affected limb; 3. Neuromuscular diseases of the lower limbs; 4. Have a history of opioid addiction; 5. Allergy to the drugs used in the trial; 6. Severe heart, lung, liver and kidney diseases; 7. Inability to cooperate with communication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative VAS pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| When analgesics are first needed;Opioid requirements in the 48 hours after surgery;Get out of bed for the first time and walk =6m time;Time from postoperative to discharge; | — |
Countries
China
Contacts
Public ContactChen Zhou
The Second Affiliated Hospital of Kunming Medical University
Outcome results
None listed